This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts
Translational Psychiatry Open Access 18 October 2022
-
Towards the clinical implementation of pharmacogenetics in bipolar disorder
BMC Medicine Open Access 30 May 2014
-
Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene
Molecular Psychiatry Open Access 23 July 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Peñas-LLedó E, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda F et al. Pharmacogenomics J; published online 28 September 2010 [e-pub ahead of print].
Zackrisson AL, Lindblom B, Ahlner J . Clin Pharmacol Ther 2010; 88: 354–359.
LLerena A, Dorado P, Peñas-Lledó EM . Pharmacogenomics 2009; 10: 17–28.
Kawanishi C, Lundgren S, Agren H, Bertilsson L . Eur J Clin Pharmacol 2004; 59: 803–807.
Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A . Pharmacogenomics 2009; 10: 1111–1120.
Acknowledgements
This study was partially supported by grants from Instituto de Salud Carlos III (ISCIII)-FIS Junta de Extremadura and European Union-FEDER BS10023, PI10/02785, PI081714 and CP06/00030 (Pedro Dorado). CIBER is an initiative of ISCIII (Spain). This study was coordinated within the network Red Iberoamericana de Farmacogenética y Farmacogenómica (http://www.ribef.com).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Peñas-Lledó, E., Dorado, P., Agüera, Z. et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 16, 691–692 (2011). https://doi.org/10.1038/mp.2011.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2011.5
This article is cited by
-
A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts
Translational Psychiatry (2022)
-
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
The Pharmacogenomics Journal (2017)
-
High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies
The Pharmacogenomics Journal (2016)
-
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
The Pharmacogenomics Journal (2015)
-
Towards the clinical implementation of pharmacogenetics in bipolar disorder
BMC Medicine (2014)